# The Effect of Atorvastatin 80 mg on Hs-CRP/Albumin Ratio in Reducing Thrombus Burden in PCI-STEMI Patients

> **NCT06871358** · NA · COMPLETED · sponsor: **Universitas Sebelas Maret** · enrollment: 40 (actual)

## Conditions studied

- STEMI (STE-ACS)
- Primary PCI for STEMI

## Interventions

- **DRUG:** Atorvastatin 80mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06871358
- **Lead sponsor:** Universitas Sebelas Maret
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-01
- **Primary completion:** 2024-10-30
- **Final completion:** 2024-11-20
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06871358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06871358, "The Effect of Atorvastatin 80 mg on Hs-CRP/Albumin Ratio in Reducing Thrombus Burden in PCI-STEMI Patients". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06871358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*